DDInter998 DDInter1678
Ivermectin is a semi-synthetic antiparasitic medication derived from avermectins, a class of highly-active broad-spectrum antiparasitic agents isolated from the fermentation products of _Streptomyces avermitilis_. Ivermectin itself is a mixture of two avermectins, comprising roughly 90% 5-O-demethyl-22,23-dihydroavermectin A<sub>1a</sub> (22,23-dihydroavermectin B<sub>1a</sub>) and 10% 5-O-demethyl-25-de(1-methylpropyl)-22,23-dihydro­-25-(1-methylethyl)avermectin A<sub>1a</sub> (22,23-dihydroavermectin B<sub>1b</sub>). Ivermectin is mainly used in humans in the
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in many types of human cancer. Sirolimus was first approved by the FDA in 1999 for the prophylaxis of organ rejection in patients aged 13 years and older receiving renal transplants. In November 2000, the drug was recognized by the European Agency as an alternative to calcineurin antagonists for maintenance therapy with corticosteroids. In May 2015, the FDA approved sirolimus for the treatment of patients with lymphangioleiomyomatosis. In November 2021, albumin-bound sirolimus for intravenous injection was approved by the FDA for the treatment of adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumour (PEComa). Sirolimus was also investigated in other cancers such as skin cancer, Kaposi’s Sarcoma, cutaneous T-cell lymphomas, and tuberous sclerosis. The topical formulation of sirolimus, marketed as HYFTOR, was approved by the FDA in April 2022: this marks the first topical treatment approved in the US for facial angiofibroma associated with tuberous sclerosis complex.
Ivermectin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Sirolimus
Ivermectin {u} (Compound) upregulates {v} (Gene) ZFP36
ZFP36 {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Ivermectin {u} (Compound) downregulates {v} (Gene) RFC5
RFC5 {u} (Gene) is downregulated by {v} (Compound) Sirolimus
Ivermectin {u} (Compound) upregulates {v} (Gene) PHGDH
PHGDH {u} (Gene) is downregulated by {v} (Compound) Sirolimus
Ivermectin {u} (Compound) causes {v} (Side Effect) Constipation
Constipation {u} (Side Effect) is caused by {v} (Compound) Sirolimus
Ivermectin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Tacrolimus
Tacrolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Ivermectin {u} (Compound) upregulates {v} (Gene) ZFP36
ZFP36 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Ivermectin {u} (Compound) upregulates {v} (Gene) VPS28
VPS28 {u} (Gene) is downregulated by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Ivermectin {u} (Compound) upregulates {v} (Gene) CTSD
CTSD {u} (Gene) is regulated by {v} (Gene) TNIP1
TNIP1 {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Ivermectin {u} (Compound) upregulates {v} (Gene) DUSP4
DUSP4 {u} (Gene) is regulated by {v} (Gene) MTOR
MTOR {u} (Gene) is bound by {v} (Compound) Sirolimus
Ivermectin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sirolimus (Compound)
Ivermectin (Compound) upregulates ZFP36 (Gene) and ZFP36 (Gene) is upregulated by Sirolimus (Compound)
Ivermectin (Compound) downregulates RFC5 (Gene) and RFC5 (Gene) is downregulated by Sirolimus (Compound)
Ivermectin (Compound) upregulates PHGDH (Gene) and PHGDH (Gene) is downregulated by Sirolimus (Compound)
Ivermectin (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Sirolimus (Compound)
Ivermectin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Tacrolimus (Compound) and Tacrolimus (Compound) resembles Sirolimus (Compound)
Ivermectin (Compound) upregulates ZFP36 (Gene) and ZFP36 (Gene) is upregulated by Everolimus (Compound) and Everolimus (Compound) resembles Sirolimus (Compound)
Ivermectin (Compound) upregulates VPS28 (Gene) and VPS28 (Gene) is downregulated by Everolimus (Compound) and Everolimus (Compound) resembles Sirolimus (Compound)
Ivermectin (Compound) upregulates CTSD (Gene) and CTSD (Gene) is regulated by TNIP1 (Gene) and TNIP1 (Gene) is upregulated by Sirolimus (Compound)
Ivermectin (Compound) upregulates DUSP4 (Gene) and DUSP4 (Gene) is regulated by MTOR (Gene) and MTOR (Gene) is bound by Sirolimus (Compound)